BioSpace News Archive

Brand Institute is proud to announce its work in developing the brand name Opvee™ (nalmefene) Nasal Spray from Indivior (through its wholly owned subsidiary, Opiant Pharmaceuticals, Inc.), which was approved by the U.S. Food and Drug Administration (FDA) on May 22, 2023.

CoSo Health today announced signing a U.S. distribution agreement with Medinol for EluNIR™, a new generation, thin-strut drug-eluting stent (DES).

XENOTHERA announces its participation in the American Society of Clinical Oncology congress, where the world’s cancer experts gather each year to share the latest clinical trial data and innovations in cancer research and education.

CANbridge Pharmaceuticals Inc. (HKEX:1228) announced that the China region of the global Phase 2 EMBARK study of LIVMARLI® (maralixibat) oral solution (CAN108) in biliary atresia (BA) is fully enrolled, with nearly twice the expected number of patients.

Versant Diagnostics announced their agreement with PRW Laboratories, a highly-distinguished dermatopathology laboratory based in Charlottesville, Va., that provides pathology services in multiple states across the nation.

On May 30, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA).

Exactech announced their first surgery in the United Arab Emirates earlier this month, which leveraged the company’s Active Intelligence® suite, using ExactechGPS® and the Equinoxe® Planning App.

Providing people with accurate and timely information to help them take their prescription medications safely and effectively is an important priority for the U.S. Food and Drug Administration.

Bristol Myers Squibb (NYSE: BMY) today announced the acceptance of two late-breaker abstracts for Breyanzi (lisocabtagene maraleucel) studies TRANSCEND FL and TRANSCEND NHL 001 for patients with relapsed or refractory follicular lymphoma (FL) and patients with relapsed or refractory mantle cell lymphoma (MCL), respectively, for presentation at the 2023 International Conference on Malignant Lymphoma (ICML).

Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), and FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company, have announced a collaboration to advance preclinical programs in neurodegeneration.